Literature DB >> 3047059

Inhibition of granulocyte function by steroids is not limited to corticoids. Studies with sex steroids.

D E Hammerschmidt1, A C Knabe, P T Silberstein, H R Lamche, P A Coppo.   

Abstract

Noting that corticosteroid doses required for protection in shock models exceeded those required to saturate glucocorticoid receptors in mammalian cells, we postulated a nonspecific physicochemical effect of steroids upon the cell membrane, and therefore tested three noncorticoid steroids for their effects on granulocyte function. All three (conjugated equine estrogen, a synthetic progestogen, and a synthetic androgen) behaved in manner analogous to corticoids at similar concentrations, inhibiting granulocyte aggregation, chemotaxis, and chemiluminescence, as well as binding to the granulocytes of the synthetic oligopeptide agonist f-Met-Leu-Phe. Estrogen was further shown to reduce granulocyte membrane fluidity, assessed by electron paramagnetic resonance. We propose that the unique effects of extremely high-dose corticosteroids are not mediated via the glucocorticoid receptor, but result rather from physicochemical effects of the drugs upon the membranes of effector cells.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3047059     DOI: 10.1007/BF00920079

Source DB:  PubMed          Journal:  Inflammation        ISSN: 0360-3997            Impact factor:   4.092


  15 in total

1.  Complement (C5-a)-induced granulocyte aggregation in vitro. A possible mechanism of complement-mediated leukostasis and leukopenia.

Authors:  P R Craddock; D Hammerschmidt; J G White; A P Dalmosso; H S Jacob
Journal:  J Clin Invest       Date:  1977-07       Impact factor: 14.808

Review 2.  Complement-induced granulocyte aggregation: an unsuspected mechanism of disease.

Authors:  H S Jacob; P R Craddock; D E Hammerschmidt; C F Moldow
Journal:  N Engl J Med       Date:  1980-04-03       Impact factor: 91.245

3.  Corticosteroids block binding of chemotactic peptide to its receptor on granulocytes and cause disaggregation of granulocyte aggregates in vitro.

Authors:  K M Skubitz; P R Craddock; D E Hammerschmidt; J T August
Journal:  J Clin Invest       Date:  1981-07       Impact factor: 14.808

4.  Protective action of estrogen in endotoxin shock.

Authors:  T Imai; N Sakuraya; T Fujita
Journal:  Jpn Circ J       Date:  1977-06

5.  Steroids in the treatment of clinical septic shock.

Authors:  W Schumer
Journal:  Ann Surg       Date:  1976-09       Impact factor: 12.969

6.  Augmentation by platelets of granulocyte aggregation in response to chemotaxins: studies utilizing an improved cell preparation technique.

Authors:  H Redl; D E Hammerschmidt; G Schlag
Journal:  Blood       Date:  1983-01       Impact factor: 22.113

7.  Corticosteroids inhibit complement-induced granulocyte aggregation. A possible mechanism for their efficacy in shock states.

Authors:  D E Hammerschmidt; J G White; P R Craddock; H S Jacob
Journal:  J Clin Invest       Date:  1979-04       Impact factor: 14.808

8.  Inhibition of arachidonic acid release from cells as the biochemical action of anti-inflammatory corticosteroids.

Authors:  S L Hong; L Levine
Journal:  Proc Natl Acad Sci U S A       Date:  1976-05       Impact factor: 11.205

9.  Specific receptor sites for chemotactic peptides on human polymorphonuclear leukocytes.

Authors:  L T Williams; R Snyderman; M C Pike; R J Lefkowitz
Journal:  Proc Natl Acad Sci U S A       Date:  1977-03       Impact factor: 11.205

10.  Leukocyte locomotion and chemotaxis. New methods for evaluation, and demonstration of a cell-derived chemotactic factor.

Authors:  S H Zigmond; J G Hirsch
Journal:  J Exp Med       Date:  1973-02-01       Impact factor: 14.307

View more
  1 in total

1.  Steroids decrease granulocyte membrane fluidity, while phorbol ester increases membrane fluidity. Studies using electron paramagnetic resonance.

Authors:  H R Lamche; P T Silberstein; A C Knabe; D D Thomas; H S Jacob; D E Hammerschmidt
Journal:  Inflammation       Date:  1990-02       Impact factor: 4.092

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.